Compare Novartis AG (NVS) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Teladoc Health Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Teladoc Health Inc trades at $9.69 (market cap $1.74B). The key difference: Novartis AG is far larger — about 166.8× Teladoc Health Inc's market cap, and Novartis AG pays a 3.17% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| NVS | TDOC | |
|---|---|---|
Market Cap | $290.25B | $1.74B |
Sector | Health | Health |
52-Week High | $168.62 | $9.72 |
52-Week Low | $113.50 | $4.47 |
Enterprise Value | $330.27B | $2.03B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
TDOC trades at $9.71, up 2.97% with a bullish technical signal. The stock shows improving fundamentals with revenue stabilizing around $2.5B and narrowing losses. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Positive sentiment is driven by partnerships like Walmart Better Care and cost-cutting initiatives, though net margins remain negative.
The outlook suggests cautious optimism as operational improvements may drive recovery, but persistent losses and high debt pose risks. Analyst consensus is mixed with 36% buy ratings and a $9.50 price target, indicating limited upside. Investors should weigh cost-control progress against competitive pressures in telehealth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
